{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:48:14Z","timestamp":1788875294254,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03368-4","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:13:10Z","timestamp":1758615190000},"page":"5781-5793","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Estimated Long-Term Durability of Valoctocogene Roxaparvovec Treatment in Male patients with Severe Hemophilia A: An Extrapolation of Clinical Data"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03370913","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02576795","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sandra","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Trueman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"1","key":"3368_CR1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12929-021-00760-4","volume":"28","author":"D Okaygoun","year":"2021","unstructured":"Okaygoun D, Oliveira DD, Soman S, Williams R. Advances in the management of haemophilia: emerging treatments and their mechanisms. J Biomed Sci. 2021;28(1):64. https:\/\/doi.org\/10.1186\/s12929-021-00760-4.","journal-title":"J Biomed Sci"},{"issue":"7","key":"3368_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6070063","volume":"6","author":"D Melchiorre","year":"2017","unstructured":"Melchiorre D, Manetti M, Matucci-Cerinic M. Pathophysiology of hemophilic arthropathy. J Clin Med. 2017;6(7):63. https:\/\/doi.org\/10.3390\/jcm6070063.","journal-title":"J Clin Med"},{"issue":"no. 5","key":"3368_CR3","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/hae.15071","volume":"30","author":"E Symington","year":"2024","unstructured":"Symington E, et al. Valoctocogene roxaparvovec gene therapy provides durable haemostatic control for up to 7 years for haemophilia A. Haemophilia. 2024;30(5):1138\u201347. https:\/\/doi.org\/10.1111\/hae.15071.","journal-title":"Haemophilia"},{"key":"3368_CR4","unstructured":"Salen P, Babiker H. \"Hemophilia A. [Updated 2023 Feb 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing,\" 2023."},{"key":"3368_CR5","unstructured":"Poon M-C, Lee A. \"BMJ Best Practice. Haemophilia. Available at: https:\/\/bestpractice.bmj.com\/topics\/en-gb\/468,\" 2022."},{"issue":"Suppl 6","key":"3368_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/hae.14046","volume":"26","author":"A Srivastava","year":"2020","unstructured":"Srivastava A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1\u2013158. https:\/\/doi.org\/10.1111\/hae.14046.","journal-title":"Haemophilia"},{"key":"3368_CR7","unstructured":"UKHCDO, \"Annual Report 2022 and Bleeding Disorder Statistics for the Financial Year 2021\/2022. Available at: http:\/\/www.ukhcdo.org\/wp-content\/uploads\/2022\/12\/UKHCDO-Annual-Report-2022-2021-22-Data.pdf [last accessed 22 January 2023].\""},{"key":"3368_CR8","unstructured":"NHS Choices. \"Haemophilia: treatment \" https:\/\/www.nhs.uk\/conditions\/haemophilia\/treatment\/ (accessed August 7th, 2018)."},{"issue":"2","key":"3368_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2450\/2012.0147-11","volume":"10","author":"M Makris","year":"2012","unstructured":"Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus. 2012;10(2):165\u20138. https:\/\/doi.org\/10.2450\/2012.0147-11.","journal-title":"Blood Transfus"},{"issue":"1","key":"3368_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/hae.14171","volume":"27","author":"S O'Hara","year":"2021","unstructured":"O\u2019Hara S, et al. Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis. Haemophilia. 2021;27(1):113\u20139. https:\/\/doi.org\/10.1111\/hae.14171.","journal-title":"Haemophilia"},{"key":"3368_CR11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200008","author":"V Jim\u00e9nez-Yuste","year":"2024","unstructured":"Jim\u00e9nez-Yuste V, et al. Burden of treatment on people with hemophilia: global real-world data. Blood. 2024. https:\/\/doi.org\/10.1182\/blood-2024-200008.","journal-title":"Blood"},{"issue":"5 Suppl","key":"3368_CR12","first-page":"s126","volume":"22","author":"SL Chen","year":"2016","unstructured":"Chen SL. Economic costs of hemophilia and the impact of prophylactic treatment on patient management. Am J Manag Care. 2016;22(5 Suppl):s126-33.","journal-title":"Am J Manag Care"},{"issue":"2","key":"3368_CR13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s41669-024-00540-4","volume":"9","author":"AA El-Sayed","year":"2025","unstructured":"El-Sayed AA, Bolous NS. Economic burden of haemophilia from a societal perspective: a scoping review. PharmacoEconomics Open. 2025;9(2):179\u2013205. https:\/\/doi.org\/10.1007\/s41669-024-00540-4.","journal-title":"PharmacoEconomics Open"},{"issue":"11","key":"3368_CR14","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2113708.","journal-title":"N Engl J Med"},{"issue":"26","key":"3368_CR15","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","volume":"377","author":"S Rangarajan","year":"2017","unstructured":"Rangarajan S, et al. AAV5\u2013factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017;377(26):2519\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1708483.","journal-title":"N Engl J Med"},{"issue":"1","key":"3368_CR16","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","volume":"382","author":"KJ Pasi","year":"2020","unstructured":"Pasi KJ, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med. 2020;382(1):29\u201340. https:\/\/doi.org\/10.1056\/NEJMoa1908490.","journal-title":"N Engl J Med"},{"issue":"8","key":"3368_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102615","volume":"8","author":"AD Leavitt","year":"2024","unstructured":"Leavitt AD, et al. Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial. Res Pract Thromb Haemost. 2024;8(8):102615. https:\/\/doi.org\/10.1016\/j.rpth.2024.102615.","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"3368_CR18","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1056\/NEJMoa2211075","volume":"388","author":"J Mahlangu","year":"2023","unstructured":"Mahlangu J, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A. N Engl J Med. 2023;388(8):694\u2013705. https:\/\/doi.org\/10.1056\/NEJMoa2211075.","journal-title":"N Engl J Med"},{"key":"3368_CR19","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241304645","volume":"15","author":"DV Quon","year":"2024","unstructured":"Quon DV, et al. Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial. Ther Adv Hematol. 2024;15:20406207241304645. https:\/\/doi.org\/10.1177\/20406207241304645.","journal-title":"Ther Adv Hematol"},{"key":"3368_CR20","unstructured":"NICE Decision Support Unit, \"Survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. Available at: http:\/\/www.nicedsu.org.uk\/Survival-analysis-TSD(2892878).htm. (Last accessed: 15 May 2013),\" 2013."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03368-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03368-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03368-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:45:22Z","timestamp":1761986722000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03368-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3368"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03368-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"David Trueman is an employee of Source Health Economics, who were funded by BioMarin to undertake this work. Sandra Santos is an employee and stockholder of BioMarin UK Ltd. Tara Robinson was an employee and stockholder of BioMarin Pharmaceutical Inc at the time of study initiation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study is a post hoc analysis of previously conducted studies and does not include the addition of new studies with human participants or animal subjects. As previously reported, the protocols for GENEr8-1 [\n                      \n                      ] and Study\u00a0270\u2013201 [\n                      \n                      ] were approved by the institutional review boards or independent ethics committees of all participating sites, and all participants provided written informed consent to participate. Both trials were performed in accordance with the ethical principles set forth by the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}